DEF: Perrigo Details 2025 Performance, Proposes 2026 LTIP

Perrigo's 2026 proxy statement reveals mixed 2025 financial results, strategic progress on its 3-S plan, and proposals for the upcoming Annual General Meeting, including a new Long-Term Incentive Plan.

Summary

• Perrigo made substantial progress on its 'Stabilize, Streamline, and Strengthen' (3-S) plan in 2025, advancing its Enterprise Strategy.
• Reported net sales for 2025 were $4.3 billion, a decrease from $4.4 billion in the prior year, primarily due to businesses under strategic review and divestitures.
• Adjusted operating income increased by 2% to $622 million, and adjusted operating margin expanded by 70 basis points to 14.6% compared to the prior year.
• Adjusted earnings per share (EPS) grew by $0.18 or 7.0% to $2.75, including a $0.10 tailwind from favorable currency translation and a $0.12 unfavorable impact from divestitures and exited products.
• Operating cash flow was $239 million, with end-of-year cash and cash equivalents at $532 million.
• Net leverage to adjusted EBITDA remained flat at 4.0x at the end of 2025.
• The company achieved gross annualized pre-tax savings of approximately $163 million from 'Project Energize' and $157 million from the 'Supply Chain Reinvention' program.
• Perrigo announced an agreement to divest its Dermacosmetics business for up to 327 million and initiated strategic reviews for its Infant Formula and Oral Care businesses.
• Executive compensation for 2025 saw base salaries increase by approximately 3%, but Annual Incentive Plan (AIP) payouts were below target due to underperformance in Net Sales, Adjusted Operating Income, and Operating Cash Flow.
• The 2023-2025 currency-neutral Adjusted Operating Income Performance Share Units (PSU OI) paid out at 91.2% of target, while the 2023-2025 Relative Total Shareholder Return (rTSR) PSUs paid out at 0% of target.
• Shareholders will vote on the election of nine director nominees, ratification of Ernst & Young LLP as independent auditor, advisory approval of executive compensation, approval of the 2026 Long-Term Incentive Plan, and renewal of share issuance and pre-emption rights authorities under Irish law.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While strategic initiatives show progress and adjusted profitability metrics improved, the decline in reported net sales, significant goodwill impairment, and underperformance in relative TSR compensation metrics temper enthusiasm.

Positives

• Substantial progress was made on the 3-S plan, including stabilizing the store brand business with 60 basis points volume share gain in the U.S. and key brands dollar share gain of 10 basis points.
• The innovation pipeline strengthened, with a potential unadjusted dollar value 3X greater than 2024.
• Customer service levels consistently achieved greater than 90% with top customers.
• Project Energize streamlining efforts achieved gross annualized pre-tax savings of approximately $163 million, towards the high-end of the estimated range.
• The Supply Chain Reinvention program successfully completed, achieving gross annualized pre-tax benefits of $157 million within the estimated range.
• Adjusted EPS grew by 7.0% to $2.75, and adjusted operating income increased by 2% to $622 million, with adjusted operating margin expanding by 70 basis points.
• The company maintained a strong balance sheet, with net leverage to adjusted EBITDA flat at 4.0x.
• Shareholders approved the 2025 executive compensation with over 98% of votes, indicating strong support for the pay-for-performance programs.

Negatives

• Reported net sales decreased to $4.3 billion in 2025 from $4.4 billion in the prior year, primarily due to businesses under strategic review and divestitures.
• Annual Incentive Plan (AIP) payouts were below target due to underperformance on Net Sales, Adjusted Operating Income, and Operating Cash Flow metrics.
• The 2023-2025 Relative Total Shareholder Return (rTSR) Performance Share Units (PSUs) paid out at 0% of target, indicating underperformance against the S&P 500 constituents.
• A goodwill impairment charge of $1.3 billion was recorded in 2025, primarily related to the CSCA and CSCI reporting units.
• Infant Formula supply stabilization was achieved, but demand recovery slowed, and competition intensified.

Risks

• The company faces strategic and competitiveness risks, financial risks, brand and reputational risks, legal and regulatory risks, operational risks, cybersecurity risks, Sustainability & Environmental, Social & Governance (Sustainability & ESG) risks, and organizational succession planning risks.
• Cybersecurity and information security risks are a significant focus, with the company employing a risk-based approach, NIST frameworks, third-party assessments, and maintaining cyber insurance coverage.
• Geoffrey M. Parker, a director nominee, was formerly CFO of Tricida, Inc., a biotechnology company that filed for bankruptcy in 2023 after its investigational drug candidate failed, highlighting potential industry-specific risks.

Future Outlook

The company is laser-focused on scaling more molecules, at more price points, to more consumers, in support of its purpose: 'Making Lives Better Through Trusted Health and Wellness Solutions, Accessible to All.' Strategic reviews for the Infant Formula and Oral Care businesses are ongoing, and political advocacy related to infant formula and women's health is expected to continue. The Board intends to propose annual renewals of its authority to issue shares and opt-out of statutory pre-emption rights.

Management Comments

• We clearly defined our Business Model to deliver a focused portfolio of consumer health solutions that delight consumers and, in partnership with our customers, improve access and accelerate category growth.
• Now, we are laser-focused on scaling more molecules, at more price points, to more consumers, in support of Our Purpose: Making Lives Better Through Trusted Health and Wellness Solutions, Accessible to All.
• Our ability to successfully execute our business strategies will depend in large part on continuing to have the right executive leadership team in place for success.

Industry Context

StockSavvy.ai notes the company's strategic focus on consumer self-care aligns with broader industry trends towards consumer empowerment in health management. The divestiture of Dermacosmetics and strategic reviews of Infant Formula and Oral Care suggest a move towards a more focused portfolio, a common strategy among diversified healthcare companies seeking to optimize performance and capital allocation. The emphasis on market share gains in store brands and key brands indicates a competitive environment where private label and established brands vie for consumer loyalty.

Comparison to Industry Standards

• The 4.0x net leverage to adjusted EBITDA is a moderate level, comparable to peers like Haleon plc (e.g., 3.5x-4.0x) or Kenvue Inc. (e.g., 3.0x-3.5x), indicating a manageable debt load for a consumer health company.
• The adjusted operating margin of 14.6% is competitive within the consumer health sector, though some premium brand-focused companies like The Estée Lauder Companies Inc. (e.g., 15-20%) might achieve higher, while more generic-focused companies might be lower.
• The 0% payout for Relative TSR PSUs suggests underperformance against the S&P 500 constituents, indicating a need for improved shareholder returns compared to broader market benchmarks.
• The 9.35% fully diluted overhang is within acceptable ranges for many public companies, though some institutional investors prefer lower dilution levels (e.g., below 10-15%).

Management Changes

Corporate Governance

Legal Proceedings

• The company incurred $59.0 million in 'Unusual litigation' as a pre-tax adjustment in 2025.

Related Party Transactions

• The Nominating & Governance Committee has determined that there are no related-party transactions requiring disclosure in this proxy statement.

Stakeholder Impact

• Shareholders: Directly impacted by the company's financial performance, strategic direction, executive compensation decisions, and proposals for the 2026 Long-Term Incentive Plan and share issuance authorities, which could lead to dilution.
• Employees: Affected by the 3-S strategic plan, which includes streamlining efforts and organizational changes, as well as human capital management initiatives focused on well-being, growth, and continuous learning.
• Customers: The company's business model aims to deliver focused consumer health solutions that delight consumers and improve access, accelerating category growth.
• Suppliers: The company is committed to upholding human rights, fair working conditions, and environmental standards in its supply chain, with rigorous monitoring programs and supplier cyber risk assessments.
• Creditors: The company maintained a strong balance sheet with net leverage to adjusted EBITDA at 4.0x, indicating a manageable debt profile.

Next Steps

• Shareholders will vote on the election of nine director nominees at the 2026 Annual General Meeting (AGM).
• Shareholders will vote on the ratification of Ernst & Young LLP as the company's independent auditor and authorize the Board to fix their remuneration.
• Shareholders will provide an advisory vote on the company's executive compensation.
• Shareholders will vote on the approval of the Perrigo Company plc 2026 Long-Term Incentive Plan.
• Shareholders will vote on the renewal of the Board's authority to issue shares under Irish law.
• Shareholders will vote on the renewal of the Board's authority to opt-out of statutory pre-emption rights under Irish law.
• The company's Irish Statutory Financial Statements for the fiscal year ended December 31, 2025, will be considered at the AGM.
• Political advocacy related to infant formula and women's health businesses is expected to continue in the current reporting period.

Key Dates

Recommendation

The company shows mixed performance with adjusted EPS growth and strategic progress on its 3-S plan, including significant cost savings. However, the decline in reported net sales, a substantial goodwill impairment, and the 0% payout on relative TSR PSUs indicate underlying challenges and underperformance against market benchmarks. The strategic reviews of key businesses like Infant Formula and Oral Care introduce uncertainty, while the proposed LTIP and share issuance authorities are standard but contribute to potential dilution. A 'Hold' recommendation reflects the balance between positive operational improvements and ongoing strategic and financial headwinds.

Keywords

Perrigo, Proxy Statement, Annual General Meeting, Executive Compensation, Long-Term Incentive Plan, Financial Performance, Strategic Plan, Divestitures, Cost Savings, Market Share, Adjusted EPS, Operating Income, Operating Margin, Corporate Governance, Cybersecurity, Risk Management, Ireland, Shareholder Vote